LipixelleTM
LipixelleTM Technology is a platform for solubilizing ophthalmic drugs with limited water solubility or completely insoluble ophthalmic drugs The currently marketed Latanoprost Eye Drops contain Benzalkonium Chloride (BAK). BAK is a common preservative in topical ocular preparations; however, prolonged use may lead to deleterious effects on the ocular surface, affecting quality of life and reducing adherence to treatment and overall outcomes.
SPARC has developed LipixelleTM Technology platform to formulate Latanoprost in to a novel clear, colorless, BAK-free Ophthalmic Emulsion.
This technology does not require the use of quaternary ammonium preservative/surfactant like Benzalkonium Chloride which may be damaging to the eye.

Key Features & Benefits
- BAK-Free platform for solubilizing ophthalmic drugs with limited water solubility or completely insoluble ophthalmic drugs
- Uses nonionic surfactant (NIS) to solubilize Latanoprost
- Contains known ocular lubricant which fortifies the lipid layer in formation of tear film, and uncharged coating is soft to eye surface
- Reduces risk of ocular surface damage on chronic use
- Prevents drug from environmental temperature and light fluctuations; stable at room temperature; does not require refrigeration upon storage / transport

LipixelleTM Technology is a platform for solubilizing ophthalmic drugs with limited water solubility or completely insoluble ophthalmic drugs The currently marketed Latanoprost Eye Drops contain Benzalkonium Chloride (BAK). BAK is a common preservative in topical ocular preparations; however, prolonged use may lead to deleterious effects on the ocular surface, affecting quality of life and reducing adherence to treatment and overall outcomes.